1. Home
  2. VRCA vs FRMM Comparison

VRCA vs FRMM Comparison

Compare VRCA & FRMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$3.78

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

FRMM

Forum Markets Incorporated Common Stock

HOLD

Current Price

$3.77

Market Cap

75.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRCA
FRMM
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
75.7M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
VRCA
FRMM
Price
$3.78
$3.77
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $13.83
$9.50
AVG Volume (30 Days)
44.6K
★ 96.6K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $35,577,000.00
$6,547,000.00
Revenue This Year
N/A
$177.58
Revenue Next Year
$58.01
$587.83
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 370.22
N/A
52 Week Low
$3.28
$1.76
52 Week High
$9.82
$7.15

Technical Indicators

Market Signals
Indicator
VRCA
FRMM
Relative Strength Index (RSI) 35.23 26.83
Support Level N/A $3.61
Resistance Level $5.94 $5.12
Average True Range (ATR) 0.35 0.25
MACD -0.05 -0.08
Stochastic Oscillator 19.48 8.44

Price Performance

Historical Comparison
VRCA
FRMM

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About FRMM Forum Markets Incorporated Common Stock

Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.

Share on Social Networks: